Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Joaquim Bellmunt; Hans von der Maase; Graham M Mead; Iwona Skoneczna; Maria De Santis; Gedske Daugaard; Andreas Boehle; Christine Chevreau; Luis Paz-Ares; Leslie R Laufman; Eric Winquist; Derek Raghavan; Sandrine Marreaud; Sandra Collette; Richard Sylvester; Ronald de Wit

doi:10.1200/JCO.2011.38.6979

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Joaquim Bellmunt, Hans von der Maase, Graham M Mead, Iwona Skoneczna, Maria De Santis, Gedske Daugaard, Andreas Boehle, Christine Chevreau, Luis Paz-Ares, Leslie R Laufman, Eric Winquist, Derek Raghavan, Sandrine Marreaud, Sandra Collette, Richard Sylvester, Ronald de Wit

403 Citations (Scopus)

Abstract

The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

Original language	English
Journal	Journal of Clinical Oncology
Volume	30
Issue number	10
Pages (from-to)	1107-13
Number of pages	7
ISSN	0732-183X
DOIs	https://doi.org/10.1200/JCO.2011.38.6979
Publication status	Published - 2012

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Transitional Cell
Cisplatin
Deoxycytidine
Disease-Free Survival
Drug Administration Schedule
Female
Hemorrhage
Humans
Male
Middle Aged
Neutropenia
Paclitaxel
Survival Analysis
Thrombocytopenia
Treatment Outcome
Urologic Neoplasms
Urothelium

Access to Document

10.1200/JCO.2011.38.6979

Fingerprint

Dive into the research topics of 'Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987'. Together they form a unique fingerprint.

Cite this

Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., Winquist, E., Raghavan, D., Marreaud, S., Collette, S., Sylvester, R., & de Wit, R. (2012). Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology, 30(10), 1107-13. https://doi.org/10.1200/JCO.2011.38.6979

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. / Bellmunt, Joaquim; von der Maase, Hans; Mead, Graham M et al.
In: Journal of Clinical Oncology, Vol. 30, No. 10, 2012, p. 1107-13.

Research output: Contribution to journal › Journal article › Research › peer-review

Bellmunt, J, von der Maase, H, Mead, GM, Skoneczna, I, De Santis, M, Daugaard, G, Boehle, A, Chevreau, C, Paz-Ares, L, Laufman, LR, Winquist, E, Raghavan, D, Marreaud, S, Collette, S, Sylvester, R & de Wit, R 2012, 'Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987', Journal of Clinical Oncology, vol. 30, no. 10, pp. 1107-13. https://doi.org/10.1200/JCO.2011.38.6979

Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology. 2012;30(10):1107-13. doi: 10.1200/JCO.2011.38.6979

@article{fec3cbb919ec4728b0b10beb92a30330,

title = "Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987",

abstract = "The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Cisplatin, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Neutropenia, Paclitaxel, Survival Analysis, Thrombocytopenia, Treatment Outcome, Urologic Neoplasms, Urothelium",

author = "Joaquim Bellmunt and \{von der Maase\}, Hans and Mead, \{Graham M\} and Iwona Skoneczna and \{De Santis\}, Maria and Gedske Daugaard and Andreas Boehle and Christine Chevreau and Luis Paz-Ares and Laufman, \{Leslie R\} and Eric Winquist and Derek Raghavan and Sandrine Marreaud and Sandra Collette and Richard Sylvester and \{de Wit\}, Ronald",

year = "2012",

doi = "10.1200/JCO.2011.38.6979",

language = "English",

volume = "30",

pages = "1107--13",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy

T2 - EORTC Intergroup Study 30987

AU - Bellmunt, Joaquim

AU - von der Maase, Hans

AU - Mead, Graham M

AU - Skoneczna, Iwona

AU - De Santis, Maria

AU - Daugaard, Gedske

AU - Boehle, Andreas

AU - Chevreau, Christine

AU - Paz-Ares, Luis

AU - Laufman, Leslie R

AU - Winquist, Eric

AU - Raghavan, Derek

AU - Marreaud, Sandrine

AU - Collette, Sandra

AU - Sylvester, Richard

AU - de Wit, Ronald

PY - 2012

Y1 - 2012

N2 - The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

AB - The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Transitional Cell

KW - Cisplatin

KW - Deoxycytidine

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Female

KW - Hemorrhage

KW - Humans

KW - Male

KW - Middle Aged

KW - Neutropenia

KW - Paclitaxel

KW - Survival Analysis

KW - Thrombocytopenia

KW - Treatment Outcome

KW - Urologic Neoplasms

KW - Urothelium

UR - https://www.scopus.com/pages/publications/84863897662

U2 - 10.1200/JCO.2011.38.6979

DO - 10.1200/JCO.2011.38.6979

M3 - Journal article

C2 - 22370319

SN - 0732-183X

VL - 30

SP - 1107

EP - 1113

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 10

ER -

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this